SkinBioTherapeutics PLC - Newcastle-based life science company focused on skin health - Receives regulatory approval to issue AxisBiotix-Ps in Italy. This follows the launch of AxisBiotix-Ps in Spain, after having received approval in March. Says the next target country for launch of the product is France, with talks with French regulators already underway. AxisBiotix-Ps is a food supplement used to alleviate Psoriasis symptoms.
Chief Executive Officer Stuart J. Ashman says: "In line with our strategic plan, we are delighted that AxisBiotix-Ps is now approved for sale into another European market, after the initial success in the UK and then Spain. We have seen high customer retention rates, and we anticipate that Italian consumers will follow this trend due to their positive attitude to food supplements. We are now awaiting the decision from the regulatory authorities in France, which is on track for later in 2023."
Current stock price: 12.55 pence, up 1.4%
12-month change: down 40%
By Sabrina Penty, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Skinbiotherap. (SBTX)